Granules India gets ANDA approval for Methylergonovine 0.2 mg Tablets

From USFDA

Granules India announced that the USFDA has approved its Abbreviated New Drug Applications (ANDA) for Methylergonovine 0.2 mg Tablets. The AN DA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 MG.

Methylergonovine is a semisynthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.

Powered by Capital Market - Live News